Ulf-Håkan Stenman

Ulf-Håkan Stenman

Auto-generated profile, based on publicly available information

Ulf-Håkan Stenman

Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in The Lancet
Verified
Journal Article
Closed access
FSFritz H Schröder
Fritz H Schröder
JHJonas Hugosson
Jonas Hugosson
Monique RoobolMonique Roobol
Monique Roobol
TTTeuvo L J Tammela
Teuvo L J Tammela
MZMarco Zappa
Marco Zappa
AAAnssi Auvinen
Anssi Auvinen

1 December 2008 in Clinical Chemistry
Verified
Journal Article
Open access
CSCatharine M Sturgeon
Catharine M Sturgeon
MDMichael J Duffy
Michael J Duffy
USUlf-HåkAn Stenman
Ulf-HåkAn Stenman
HLHans Lilja
Hans Lilja
NBNils BrünNer
Nils BrünNer
EDEleftherios P Diamandis
Eleftherios P Diamandis
Background: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed.Methods: Published reports relevant to use of tumor markers for 5 cancer sites—testicular, prostate, colorectal, breast, and ovarian—were critically reviewed.Results: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 μg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node–negative patients. CA15-3/BR27–29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer.Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers.

1 July 2004 in Clinical Biochemistry
Verified
Journal Article
Closed access
USUlf-Håkan Stenman
Ulf-Håkan Stenman
HAHenrik Alfthan
Henrik Alfthan
KHKristina Hotakainen
Kristina Hotakainen

28 July 2006 in Human Reproduction Update
Verified
Journal Article
Open access
PDF file
USUlf-Håkan Stenman
Ulf-Håkan Stenman
ATAila Tiitinen
Aila Tiitinen
HAHenrik Alfthan
Henrik Alfthan
LVLeena Valmu
Leena Valmu
HCG is composed of two subunits, HCGα and HCGβ. During early pregnancy, HCG stimulates progesterone production in the corpus luteum, and injection of HCG is widely used to induce ovulation in assisted reproduction treatment (ART). Under experimental conditions, the free subunits have been shown to exert functions other than those of HCG, but the relevance of these remains to be determined. Intact HCG, free subunits and degraded forms of these occur in biological fluids, and determinations of these are important for diagnosis and monitoring of pregnancy, pregnancy-related disorders and several types of cancer. Development of optimal methods for the various forms has been hampered by lack of appropriate standards and expression of the concentrations of the various forms in units that are not comparable. Furthermore, the nomenclature for HCG assays is confusing and in some cases misleading. These problems can now be solved; a uniform nomenclature has been established, and new standards are available for HCG, its subunits HCGα and HCGβ, the partially degraded or nicked forms of HCG and HCGβ, and the beta-core fragment. This review describes the biochemical and biological background for the clinical use of determinations of various forms of HCG. The clinical use of HCG and studies on HCG vaccines are briefly reviewed.

1 October 2009 in European Urology
Verified
Journal Article
Closed access
Monique RoobolMonique Roobol
Monique Roobol
MKMelissa Kerkhof
Melissa Kerkhof
FSFritz H. Schröder
Fritz H. Schröder
JCJack Cuzick
Jack Cuzick
PSPeter Sasieni
Peter Sasieni
AAAnssi Auvinen
Anssi Auvinen

1 January 2011 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
TKTanja Kuiri-Hänninen
Tanja Kuiri-Hänninen
RSRaija Seuri
Raija Seuri
ETErja Tyrväinen
Erja Tyrväinen
UTUrsula Turpeinen
Ursula Turpeinen
EHEsa Hämäläinen
Esa Hämäläinen
USUlla Sankilampi
Ulla Sankilampi
Transient activation of the hypothalamic-pituitary-gonadal (HPG) axis is observed in boys during the first months of life. Previous research suggests increased HPG axis activation in premature infants, but the physiological significance of this has not been studied. The objective of this study was to evaluate the differences in reproductive hormone levels and their biological effects between full-term (FT) and preterm (PT) infant boys. Twenty-five FT and 25 PT (gestational age 24.7-36.6 wk) boys were recruited at birth and followed up monthly from 1 wk to 6 months of age (d 7, months 1-6). Nineteen FT and 20 PT boys were reexamined at 14 months of age. Urinary gonadotropins and testosterone were measured in serial urine samples and compared with testicular and penile growth. Urinary prostate-specific antigen was measured as an androgen biomarker. LH and testosterone levels were higher in PT boys (P < 0.001 for both) than FT boys. Compared with FT boys, FSH levels were lower at d 7 (P = 0.002) but higher from month 1 to month 3 (P = 0.002-0.030) in PT boys. This was associated with significantly faster testicular and penile growth in PT boys compared with FT boys. Transient increase in the prostate-specific antigen levels in both groups indicated androgen action in the prostate. Postnatal HPG axis activation in infancy is increased in PT boys and associated with faster testicular and penile growth compared with FT boys. Possible long-term consequences of hyperandrogenism in PT infant boys warrant further research.